Sep 18, 2020 7:00 am EDT Achieve Life Sciences Announces Results from Evaluation of Cytisinicline (cytisine) versus Chantix® (varenicline) in 5-HT3 Receptor Binding Assay Study
Sep 10, 2020 5:30 am EDT Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 20th Annual Society for Research on Nicotine & Tobacco Europe (SRNT-E) Virtual Conference
Aug 6, 2020 4:05 pm EDT Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program
Jul 31, 2020 8:30 am EDT Achieve Announces Patent Granted in the U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications
Jul 28, 2020 5:30 am EDT Achieve Life Sciences to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020
Jun 29, 2020 8:35 am EDT Achieve Life Sciences Announces Pricing of $6 Million Registered Direct Offering
Jun 29, 2020 8:30 am EDT Achieve Announces Successful Results from the Investigator-Initiated RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix® (varenicline) as a Treatment to Quit Smoking